Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02081404 · ClinicalTrials.gov registry record · NA
Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study
A NA study, sponsored by Midwest Biomedical Research Foundation.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
NCT02081404: Completed NA study, sponsored by Midwest Biomedical Research Foundation.
NCT02081404 is a NA study that has completed, run by Midwest Biomedical Research Foundation. The registered enrollment target is 98 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02081404, a NA study, has completed, sponsored by Midwest Biomedical Research Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
Study Summary
Gastroesophageal reflux disease (GERD), a common chronic disorder in the veteran population, is associated with drug costs exceeding $ 10 billion/year. Only 30-40% of patients with reflux symptoms have erosive esophagitis. The vast majority suffers from non erosive reflux disease (NERD), a condition in which standard endoscopy fails to identify any mucosal breaks and is unable to confirm the diagnosis. Unfortunately, a gold standard for the diagnosis of NERD does not exist. Narrow band imaging (NBI) utilizes spectral narrow band filters (incorporated into standard endoscopes) and helps to see abnormal areas not identified during standard endoscopy. Preliminary results have shown that NBI endoscopy may represent a significant improvement over standard endoscopy for the diagnosis of NERD. The purpose of this study is to accurately diagnosis non acid reflux disease by using a blue light (also known as NBI)upper endoscopy technique.
Primary Outcome
1. Proportion of patients with NBI abnormalities in the NERD group vs. controls. 2. Proportion of patients with resolution of NBI abnormalities after PPI therapy.
Interventions
- DRUG Placebo
- DRUG Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-03-01 |
| Est. Completion | 2020-08-05 |
| Phase | NA |
What the finished NCT02081404 record still lists
NCT02081404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02081404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02081404 about?
NCT02081404 is a clinical study titled "Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study". Gastroesophageal reflux disease (GERD), a common chronic disorder in the veteran population, is associated with drug costs exceeding $ 10 billion/year. Only 30-40% of patients with reflux symptoms have erosive esophagitis. The vast majority suffers from non erosive reflux disease (NERD), a condition...
What is the current status of trial NCT02081404?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2009-03-01. Estimated completion is 2020-08-05.
What interventions are being tested in trial NCT02081404?
The interventions under investigation include: Placebo (DRUG), Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT02081404?
This trial is sponsored by Midwest Biomedical Research Foundation, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02081404's enrollment target sits among peer trials
98 922nd of 2000 higher than 1,078 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI